CU20130134A7 - Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas - Google Patents
Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidasInfo
- Publication number
- CU20130134A7 CU20130134A7 CU2013000134A CU20130134A CU20130134A7 CU 20130134 A7 CU20130134 A7 CU 20130134A7 CU 2013000134 A CU2013000134 A CU 2013000134A CU 20130134 A CU20130134 A CU 20130134A CU 20130134 A7 CU20130134 A7 CU 20130134A7
- Authority
- CU
- Cuba
- Prior art keywords
- compound
- pharmaceutical composition
- expression
- active agents
- dihydroimidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
Abstract
Uso de un compuesto de 2,3 - dihidroimidazo [ 1,2 - c] quinazolina, o de una composición farmacéutica que contiene el mismo, como agente activo único, o de una combinación de a) dicho compuesto o una composición farmacéutica que contiene dicho compuesto y b) uno o más agentes activos adicionales, para la preparación de un medicamento para el tratamiento o profilaxis de cáncer; combinaciones de a) dicho compuesto y b) uno o más agentes activos adicionales; una composición farmacéutica que comprende dicho compuesto como agente activo único para el tratamiento de cáncer de mama; una composición farmacéutica que comprende una combinación de a) dicho compuesto y b) uno o más agentes activos adicionales; uso de biomarcadores involucrados en la modificación de la expresión de Bcl, expresión y/o activación de la familia HER, señalización por PIK3CA y/o pérdida de PTEN para predecir la sensibilidad y/o resistencia de un paciente con cáncer a dicho compuesto y proveer una combinación sinérgica basada en la razón, como se define en la presente, para incrementar la sensibilidad y/o para superar la resistencia; y un método para determinar el nivel de un componente de uno o más de expresión de Bcl, expresión y/o activación de la familia HER, señalización por PIK3CA y/o pérdida de PTEN.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161142 | 2011-04-05 | ||
| PCT/EP2012/055595 WO2012136549A1 (en) | 2011-04-05 | 2012-03-29 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20130134A7 true CU20130134A7 (es) | 2014-01-29 |
| CU24349B1 CU24349B1 (es) | 2018-06-05 |
Family
ID=45894478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2013000134A CU24349B1 (es) | 2011-04-05 | 2012-03-29 | Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10202385B2 (es) |
| EP (1) | EP2694069A1 (es) |
| JP (1) | JP6013446B2 (es) |
| KR (1) | KR102006033B1 (es) |
| CN (1) | CN103608018B (es) |
| AP (1) | AP3751A (es) |
| AR (1) | AR088730A1 (es) |
| AU (2) | AU2012238887A1 (es) |
| BR (1) | BR112013025517A2 (es) |
| CA (1) | CA2832120C (es) |
| CL (1) | CL2013002869A1 (es) |
| CU (1) | CU24349B1 (es) |
| DO (1) | DOP2013000224A (es) |
| EA (1) | EA027670B1 (es) |
| EC (1) | ECSP13013007A (es) |
| GT (1) | GT201300235A (es) |
| IL (1) | IL228435A0 (es) |
| JO (1) | JO3733B1 (es) |
| MA (1) | MA35015B1 (es) |
| MX (1) | MX2013011582A (es) |
| MY (1) | MY169532A (es) |
| PE (1) | PE20140571A1 (es) |
| PH (1) | PH12013502066A1 (es) |
| SG (1) | SG193577A1 (es) |
| TN (1) | TN2013000402A1 (es) |
| TW (1) | TWI639599B (es) |
| UA (1) | UA114177C2 (es) |
| UY (1) | UY33984A (es) |
| WO (1) | WO2012136549A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| KR20180080358A (ko) | 2011-01-10 | 2018-07-11 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EA031493B9 (ru) | 2013-04-08 | 2019-12-18 | Байер Фарма Акциенгезельшафт | Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) |
| WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| US20150320755A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| KR101665234B1 (ko) * | 2015-02-10 | 2016-10-12 | 순천향대학교 산학협력단 | 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| MX2017011635A (es) | 2015-03-09 | 2018-02-09 | Bayer Pharma AG | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| CA3068324A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| US11253522B2 (en) * | 2018-04-28 | 2022-02-22 | The Regents Of The University Of California | Cancer treatment targeted to tumor adaptive responses to protein synthesis stress |
| EP3843743A1 (en) * | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
| US1539891A (en) | 1920-08-09 | 1925-06-02 | Harry A Lewis | Magnetic lifting device |
| US1450048A (en) | 1921-09-24 | 1923-03-27 | Mary S Patterson | Nut lock |
| BE397809A (es) | 1932-08-25 | |||
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US20040180846A1 (en) * | 2001-03-01 | 2004-09-16 | Ruo-Pan Huang | Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation |
| JP2005532070A (ja) * | 2002-07-03 | 2005-10-27 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Ｍｄａ−７媒介型アポトーシスの調節因子の同定方法 |
| ES2312843T3 (es) | 2002-09-30 | 2009-03-01 | Bayer Healthcare Ag | Derivados de azolpirimidina condensados. |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| JP5190233B2 (ja) | 2006-09-01 | 2013-04-24 | パナソニック株式会社 | 無線通信装置 |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| EP2244721A4 (en) * | 2008-01-14 | 2017-01-18 | Bayer Intellectual Property GmbH | Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| WO2009126172A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
| MX2010011435A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
| FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
| US8128386B2 (en) | 2008-06-26 | 2012-03-06 | Hamilton Sundstrand Corporation | Variable flow pumping system |
| EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| JP5336306B2 (ja) | 2008-10-20 | 2013-11-06 | 信越化学工業株式会社 | レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料 |
| ES2550181T3 (es) | 2009-05-14 | 2015-11-05 | Bayer Intellectual Property Gmbh | Respuesta inmunitaria reforzada en especies aviares |
| CA2796253A1 (en) * | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| PL2654785T3 (pl) | 2010-12-22 | 2019-09-30 | Bayer Intellectual Property Gmbh | Wzmocniona odpowiedź immunologiczna u gatunków wołowatych |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2014045415A1 (ja) | 2012-09-21 | 2014-03-27 | トヨタ自動車株式会社 | ハイブリッド車両用駆動装置 |
-
2012
- 2012-03-27 JO JOP/2012/0065A patent/JO3733B1/ar active
- 2012-03-28 UY UY0001033984A patent/UY33984A/es not_active Application Discontinuation
- 2012-03-28 AR ARP120101035A patent/AR088730A1/es unknown
- 2012-03-28 TW TW101110917A patent/TWI639599B/zh not_active IP Right Cessation
- 2012-03-29 EA EA201301106A patent/EA027670B1/ru not_active IP Right Cessation
- 2012-03-29 UA UAA201312764A patent/UA114177C2/uk unknown
- 2012-03-29 KR KR1020137028953A patent/KR102006033B1/ko not_active Expired - Fee Related
- 2012-03-29 EP EP12710955.1A patent/EP2694069A1/en not_active Withdrawn
- 2012-03-29 PE PE2013002187A patent/PE20140571A1/es not_active Application Discontinuation
- 2012-03-29 MA MA36289A patent/MA35015B1/fr unknown
- 2012-03-29 SG SG2013071121A patent/SG193577A1/en unknown
- 2012-03-29 CA CA2832120A patent/CA2832120C/en active Active
- 2012-03-29 AU AU2012238887A patent/AU2012238887A1/en not_active Abandoned
- 2012-03-29 US US14/009,751 patent/US10202385B2/en active Active
- 2012-03-29 AP AP2013007147A patent/AP3751A/en active
- 2012-03-29 CN CN201280027514.5A patent/CN103608018B/zh not_active Expired - Fee Related
- 2012-03-29 BR BR112013025517A patent/BR112013025517A2/pt not_active Application Discontinuation
- 2012-03-29 WO PCT/EP2012/055595 patent/WO2012136549A1/en not_active Ceased
- 2012-03-29 JP JP2014503077A patent/JP6013446B2/ja not_active Expired - Fee Related
- 2012-03-29 MY MYPI2013701876A patent/MY169532A/en unknown
- 2012-03-29 PH PH1/2013/502066A patent/PH12013502066A1/en unknown
- 2012-03-29 MX MX2013011582A patent/MX2013011582A/es unknown
- 2012-03-29 CU CUP2013000134A patent/CU24349B1/es unknown
-
2013
- 2013-09-15 IL IL228435A patent/IL228435A0/en unknown
- 2013-10-03 TN TNP2013000402A patent/TN2013000402A1/fr unknown
- 2013-10-04 DO DO2013000224A patent/DOP2013000224A/es unknown
- 2013-10-04 CL CL2013002869A patent/CL2013002869A1/es unknown
- 2013-10-04 GT GT201300235A patent/GT201300235A/es unknown
- 2013-11-04 EC ECSP13013007 patent/ECSP13013007A/es unknown
-
2017
- 2017-05-24 AU AU2017203474A patent/AU2017203474B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20130134A7 (es) | Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas | |
| DOP2015000256A (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
| UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| ECSP15030799A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| ECSP13012618A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| ES2609857T3 (es) | 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H-imidazo[4,5-C]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominios | |
| GT201300180A (es) | "compuesto de imidazo (4,5-c) quinolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor" | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| CL2013000718A1 (es) | Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades. | |
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| NI201500118A (es) | Imidazopiridazinas sustituidas | |
| CR20160235A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| GB201105050D0 (en) | Pharmaceutical agent | |
| BR112013019680A2 (pt) | combinações compreendendo macitentana para o tratamento de glioblastoma multiforme | |
| MX336204B (es) | Una composicion y uso de la misma en el tratamiento de ragades anales. | |
| PE20142020A1 (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| TN2010000611A1 (en) | Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |